![Cornelis Kees](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cornelis Kees
Chief Executive Officer at BIAL-Biotech Investments, Inc.
Cornelis Kees active positions
Companies | Position | Start | End |
---|---|---|---|
Rodin Therapeutics, Inc.
![]() Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Director/Board Member | - | - |
ReWind Therapeutics NV
![]() ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Director/Board Member | 02/09/2020 | - |
BIAL-Biotech Investments, Inc. | Chief Executive Officer | - | - |
Career history of Cornelis Kees
Former positions of Cornelis Kees
Companies | Position | Start | End |
---|---|---|---|
Monsanto Life Sciences Co. | Corporate Officer/Principal | 01/04/1999 | 01/04/1999 |
Gemini Consulting Group, Inc.
![]() Gemini Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Gemini Consulting Group, Inc. provides management consulting services. Its services range from management consulting, to the development of day surgery centers and hospitals. The company was founded by James B. McCarthy and is headquartered in Oak Brook, IL. | Corporate Officer/Principal | 01/01/1988 | - |
VIVORYON THERAPEUTICS N.V. | Director/Board Member | 01/01/2015 | - |
Lysosomal Therapeutics, Inc.
![]() Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Director/Board Member | 01/01/2011 | - |
Chief Executive Officer | 01/01/2011 | - | |
Founder | 01/01/2011 | - | |
President | 01/01/2011 | - | |
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
FORUM Pharmaceuticals, Inc.
![]() FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | President | - | - |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - | - |
Training of Cornelis Kees
INSEAD | Masters Business Admin |
Statistics
International
United States | 9 |
France | 2 |
Germany | 2 |
Operational
Director/Board Member | 4 |
President | 3 |
Corporate Officer/Principal | 3 |
Sectoral
Health Technology | 8 |
Commercial Services | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
VIVORYON THERAPEUTICS N.V. | Health Technology |
Private companies | 9 |
---|---|
Biogen MA, Inc.
![]() Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Gemini Consulting Group, Inc.
![]() Gemini Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Gemini Consulting Group, Inc. provides management consulting services. Its services range from management consulting, to the development of day surgery centers and hospitals. The company was founded by James B. McCarthy and is headquartered in Oak Brook, IL. | Commercial Services |
FORUM Pharmaceuticals, Inc.
![]() FORUM Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology FORUM Pharmaceuticals, Inc. was engaged in the development of therapeutics for disorders of the central nervous system (CNS). It focused on discovering and developing treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provided improvement in cognitive and overall function. The company was founded by Thorsten Melcher in 2001 and was headquartered in Waltham, MA. | Health Technology |
Bionaut Pharmaceuticals, Inc.
![]() Bionaut Pharmaceuticals, Inc. BiotechnologyHealth Technology Bionaut Pharmaceuticals, Inc. develops and manufactures pharmaceuticals. It is a Biotechnology company using its technology to discover and advance novel small molecule drug candidates that affect well-validated disease pathways. Bionaut's business strategy is to license its candidates at a late preclinical stage to pharmaceutical and large biotech companies for development. The company was founded in August, 2000 by Mehran M. Khodadoust & Thomas Klein and is headquartered at Cambridge, MA. | Health Technology |
Monsanto Life Sciences Co. | |
Rodin Therapeutics, Inc.
![]() Rodin Therapeutics, Inc. BiotechnologyHealth Technology Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Lysosomal Therapeutics, Inc.
![]() Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
ReWind Therapeutics NV
![]() ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier. | Health Technology |
BIAL-Biotech Investments, Inc. |
- Stock Market
- Insiders
- Cornelis Kees
- Experience